# FDA 483 - Jiangsu Hansoh Pharmaceutical Group Co., Ltd - June 13, 2019

Source: https://www.globalkeysolutions.net/records/483/jiangsu-hansoh-pharmaceutical-group-co-ltd/b4c214ad-3e91-4467-97b4-d9b4363be304

> FDA 483 for Jiangsu Hansoh Pharmaceutical Group Co., Ltd on June 13, 2019. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Jiangsu Hansoh Pharmaceutical Group Co., Ltd
- Inspection Date: 2019-06-13
- Product Type: drugs
- Office Name: Office of Biological Products Operations - Division I
- Summary: An FDA inspection of Jiangsu Hansoh Pharmaceutical Group Co. Ltd. in Lianyungang, China, a finished drug product manufacturer, revealed significant deficiencies in their production and process control systems. Observations included a lack of written procedures for assuring drug product quality, failure to follow established procedures, and inadequate validation of manufacturing processes. The firm also lacked appropriate sampling procedures for incoming components, indicating a broad failure in quality assurance.

## Related Documents

- [483 - Unknown Date](https://www.globalkeysolutions.net/records/483/jiangsu-hansoh-pharmaceutical-group-co-ltd/befa76f3-aa80-41d4-8db5-7f879f6a30e9)

## Related Officers

- [Laurimer Kuilan-Torres](https://www.globalkeysolutions.net/people/laurimer-kuilan-torres/a7f49e33-9d35-4dfe-8bcc-d369d3834ef4)

Company: https://www.globalkeysolutions.net/companies/jiangsu-hansoh-pharmaceutical-group-co-ltd/05c8e8c4-3ef9-4644-9f70-ddabbded9eec

Office: https://www.globalkeysolutions.net/offices/office-of-biological-products-operations-division-i/49c53dac-7724-4c8c-8708-4f5779ea69c1